"I know this year we're going to see even more companies producing more products, more results, and hopefully really help change and improve patient outcomes, especially when it comes to overactive bladder," says Raveen Syan, MD, FPMRS.
Frontline treatment approaches recommended by urologists and medical oncologists for patients with non-metastatic muscle-invasive bladder cancer.
"At ASCO GU, we presented the final analysis of the study, which confirmed the superiority of a combination over the TKI monotherapy in terms of both progression-free survival as well as overall survival," says Camillo Porta, MD.
Increasing numbers of older patients with cancer necessitates adoption of an age-friendly approach to cancer care.
“We're really excited as robotic surgeons, because this will be the first time in a couple decades that there'll be competition for robots, and that's only going to make things better,” says Ronney Abaza, MD, FACS.
Cretostimogene grenadenorepvec is an intravesical oncolytic immunotherapy currently under investigation in phase 3 trials.
Andrew Sun, MD, joins Pearls & Perspectives to discuss innovative approaches to testosterone therapy for enhanced health outcomes.
This monotherapy was safe for all doses and dosing schedules observed in the study and daily doses showed initial antitumor activity.
Advances allow for more accurate detection of metastatic disease.
According to Sanda, future advancements may involve gene and RNA sequencing, the use of AI in imaging, and multidisciplinary collaboration.
"It is important as a field that we recognize the potential emotional impact of surgical adverse events," writes Amy N. Luckenbaugh, MD.
Urologist Garrett D. Pohlman, MD, reflects on the benign prostatic hyperplasia offerings from the 2025 American Urological Association Annual Meeting.
"Based on the LEA and S1011 trials, it has become clear that patients do not benefit from an extended LND, and a standard bilateral pelvic LND is the standard of care," write Amir Soltani-Tehrani, MD, and Kamal S. Pohar, MD.
Dr Daniel Allan Hamstra highlights ongoing and planned trials investigating rectal spacers in patients with prostate cancer undergoing radiation therapy that he hopes will provide more data on toxicity reduction and preservation of sexual function.
Arpeet Shah, MD, highlights the shift toward precision medicine, ongoing work force challenges, the integration of AI, and more.
Joseph Jacob, MD, outlines key findings on TAR-200 monotherapy from cohort 2 of the SunRISe-1 study.
Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
“The patients I find that have the most pronounced benefit are the patients with the very large prostates, or the patients who are catheter dependent with concern for neurogenic or myogenic bladder failure,” says Brendan M. Browne, MD.
Program encompasses patient counseling, anesthetic planning, and early mobilization.
This year, the AACU 2024 Advocacy Summit & Annual Meeting will focus on the intersection of health policy and clinical practice, as well as the impact of current state and national legislative trends on urology.
“Oftentimes, [during] the very first visit, we are talking a lot. I am learning what's going on with them," says Anna Myers, CNP.
Jack R. Andrews, MD; Eugene B. Cone MD; and Edwin Posadas, MD, FACP, discuss how early intervention with individualized treatment approaches based on disease volume, patient characteristics, and biomarkers significantly improves survival outcomes in metastatic hormone-sensitive prostate cancer.
James C. Ulchaker, MD, shares his insights on the current range of BPH therapies.
Treatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.
"Augmented biopsy-based and noninvasive options are available to reduce benign resection rates of renal tumors with the consideration of PEER and 99mTc-sestamibi SPECT/CT," writes Hiten D. Patel, MD, MPH.
"Ultimately, there is no 'right choice' when it comes to urinary diversion," writes Anne K. Schuckman, MD.
Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.
Urinary tract infections (UTIs) are among the most common human infections. But the urine culture, the cornerstone for laboratory diagnosis of UTI, is imperfect.